Search research articles
Contact Us
Filters
Showing results (301-310 of 353) with videos related to
Page
of 36
Sort By:
Coronary Artery Disease
|
February 28, 2013
Quantification of the effect of clopidogrel on enzymatic infarct size related to a percutaneous coronary intervention in patients with acute coronary syndromes: insights from the CHAMPION percutaneous coronary intervention trial
Sergio Leonardi, Amanda Stebbins, Renato D Lopes, et al.
Circulation
|
March 30, 2011
2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines
Jeffrey L Anderson, Cynthia D Adams, Elliott M Antman, et al.
European Heart Journal
|
October 12, 2017
Differential blood pressure effects of ibuprofen, naproxen, and celecoxib in patients with arthritis: the PRECISION-ABPM (Prospective Randomized Evaluation of Celecoxib Integrated Safety Versus Ibuprofen or Naproxen Ambulatory Blood Pressure Measurement) Trial
Frank Ruschitzka, Jeffrey S Borer, Henry Krum, et al.
The New England Journal of Medicine
|
December 14, 2016
Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis
Steven E Nissen, Neville D Yeomans, Daniel H Solomon, et al.
Clinical Cardiology
|
August 21, 2018
Assessment of omega-3 carboxylic acids in statin-treated patients with high levels of triglycerides and low levels of high-density lipoprotein cholesterol: Rationale and design of the STRENGTH trial
Stephen J Nicholls, A Michael Lincoff, Dianna Bash, et al.
Journal of Thrombosis and Thrombolysis
|
October 19, 2010
Predictive value of C-reactive protein on 30-day and 1-year mortality in acute coronary syndromes: an analysis from the ACUITY trial
Adriano Caixeta, Gregg W Stone, Roxana Mehran, et al.
Lancet (London, England)
|
September 2, 2024
Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials
Mikhail N Kosiborod, John Deanfield, Richard Pratley, et al.
The American Journal of Cardiology
|
April 28, 2004
Comparison of bivalirudin versus heparin during percutaneous coronary intervention (the Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events [REPLACE]-1 trial)
A Michael Lincoff, John A Bittl, Neal S Kleiman, et al.
JAMA
|
April 5, 2008
Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial
Steven E Nissen, Stephen J Nicholls, Kathy Wolski, et al.
JAMA Cardiology
|
May 16, 2021
Association Between Achieved ω-3 Fatty Acid Levels and Major Adverse Cardiovascular Outcomes in Patients With High Cardiovascular Risk: A Secondary Analysis of the STRENGTH Trial
Steven E Nissen, A Michael Lincoff, Kathy Wolski, et al.
Page
of 36
Search research articles
Search
Showing results (301-310 of 353) with videos related to
Sort By:
Page
of 36
Coronary Artery Disease
|
February 28, 2013
Quantification of the effect of clopidogrel on enzymatic infarct size related to a percutaneous coronary intervention in patients with acute coronary syndromes: insights from the CHAMPION percutaneous coronary intervention trial
Sergio Leonardi, Amanda Stebbins, Renato D Lopes, et al.
Circulation
|
March 30, 2011
2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines
Jeffrey L Anderson, Cynthia D Adams, Elliott M Antman, et al.
European Heart Journal
|
October 12, 2017
Differential blood pressure effects of ibuprofen, naproxen, and celecoxib in patients with arthritis: the PRECISION-ABPM (Prospective Randomized Evaluation of Celecoxib Integrated Safety Versus Ibuprofen or Naproxen Ambulatory Blood Pressure Measurement) Trial
Frank Ruschitzka, Jeffrey S Borer, Henry Krum, et al.
The New England Journal of Medicine
|
December 14, 2016
Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis
Steven E Nissen, Neville D Yeomans, Daniel H Solomon, et al.
Clinical Cardiology
|
August 21, 2018
Assessment of omega-3 carboxylic acids in statin-treated patients with high levels of triglycerides and low levels of high-density lipoprotein cholesterol: Rationale and design of the STRENGTH trial
Stephen J Nicholls, A Michael Lincoff, Dianna Bash, et al.
Journal of Thrombosis and Thrombolysis
|
October 19, 2010
Predictive value of C-reactive protein on 30-day and 1-year mortality in acute coronary syndromes: an analysis from the ACUITY trial
Adriano Caixeta, Gregg W Stone, Roxana Mehran, et al.
Lancet (London, England)
|
September 2, 2024
Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials
Mikhail N Kosiborod, John Deanfield, Richard Pratley, et al.
The American Journal of Cardiology
|
April 28, 2004
Comparison of bivalirudin versus heparin during percutaneous coronary intervention (the Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events [REPLACE]-1 trial)
A Michael Lincoff, John A Bittl, Neal S Kleiman, et al.
JAMA
|
April 5, 2008
Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial
Steven E Nissen, Stephen J Nicholls, Kathy Wolski, et al.
JAMA Cardiology
|
May 16, 2021
Association Between Achieved ω-3 Fatty Acid Levels and Major Adverse Cardiovascular Outcomes in Patients With High Cardiovascular Risk: A Secondary Analysis of the STRENGTH Trial
Steven E Nissen, A Michael Lincoff, Kathy Wolski, et al.
Page
of 36